Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy

NCT03941964 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03941964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03941964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Single-Arm, Multicenter Open-Label Study of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in AML Patients Ineligible for Intensive Chemotherapy
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
August 15, 2019
Completion date
March 14, 2022
Enrollment
60 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), cancer